Citations

Showing 10 of 108015 citations.

Skin Substitutes: Filling the Gap in the Reconstructive Algorithm
Fuenmayor, Pedro , Huaman, Gustavo , Maita, Karla C. , Schwemmer, Kelly, Soliman, Wes, Pintos, Stephanie, González, Edward , Castrellon, Ricardo , Abdelmoneim, Sahar S. , Dickinson, Mark , Gonzalez, Edward

Mayo Clinic

Trauma Care | May 3, 2024 | Volume: 4 | Issue: 2 | Pages: 148-166

10.3390/traumacare4020012 Get It

Background: Skin substitutes play a crucial role in wound care by actively modulating the wound healing process, promoting angiogenesis, and protecting the integrity of the native extracellular matrix. Consequently, surgeons have increasingly recognized these resources as excellent complements to improve reconstructive outcomes. This review focuses on the author’s experience using these biomaterials in complex cases, highlighting the benefits they bring to patient care. Methods: A literature review was conducted to evaluate the regenerative properties of skin substitutes and their applicability in head and neck, upper and lower extremities, and trunk reconstruction. Results: The reviewed literature, along with the authors’ experience, supports the adjunct use of skin substitutes in various reconstructive situations. Combining them with skin grafts improves resulting skin quality and may also enhance donor site healing. They have proven to be effective in addressing chronic venous ulcers, traumatic wounds with limited donor tissues for coverage, extensive burns, diabetic foot ulcers, and oncological resections in the face and scalp. Furthermore, combining them with autologous tissue shows promising results in achieving stable closure. Conclusions: Incorporating skin substitutes in complex reconstructive scenarios offers multiple benefits. Their regenerative properties and ability to modulate the healing process contribute to enhanced outcomes and reduced overall costs.
Healthcare use and out‐of‐pocket costs for rural family caregivers and care recipients in a randomized controlled trial
Kaufman, Brystana G. , Huang, Ro W. , Holland, Diane E. , Vanderboom, Catherine E., Ingram, Cory , Wild, Ellen, Dose, Ann Marie , Stiles, Carole, Gustavson, Allison M. , Mandrekar, Jay , Houtven, Courtney H. Van , Wild, Ellen M, Griffin, Joan M.

Mayo Clinic

Journal of the American Geriatrics Society | May 3, 2024 | Volume: 72 | Issue: 8 | Pages: 2523-2531

10.1111/jgs.18934 | PMID 38698643 Get It

Abstract Background Rural family caregivers (FCGs) in the United States often experience high economic costs. This randomized controlled trial compared a transitional palliative care intervention (TPC) to support FCGs of seriously ill care recipients (CRs) to an attention control condition. We evaluated the TPC's effect on healthcare use and out‐of‐pocket spending for both FCGs and CRs. Methods TPC FCGs received teaching, guidance, and counseling via video calls for 8 weeks following CR discharge from the hospital. After discharge, a research assistant called all FCGs once a month for up to 6 months or CR death to collect self‐reported healthcare utilization (e.g., outpatient, emergency department, and hospital), out‐of‐pocket healthcare spending (e.g., deductibles and coinsurance), and health‐related travel costs (e.g., transportation, lodging, food) for FCGs and CRs. Incidence rate ratios (IRRs) were estimated using negative binomial regressions. Results The study included 282 FCG–CR dyads across three U.S. states. Follow‐up over the 6‐month period was shortened by high CR mortality rates across both arms (29%), but was similar across arms. TPC reduced nights in the hospital for CR (IRR = 0.75; 95% confidence interval [CI] = 0.56–0. 99). Total out‐of‐pocket spending was not significantly different for TPC versus control. Across both groups, mean out‐of‐pocket spending for dyads was $1401.85, with healthcare payments contributing $1048.58 and transportation expenses contributing $136.79. TPC dyads reported lower lodging costs (IRR = 0.71; 95% CI = 0.56–0.89). Conclusions This study contributes to evidence that palliative care interventions reduce the number of nights in the hospital for seriously ill patients. Yet, overall rural FCGs and seriously ill CRs experience substantial out‐of‐pocket economic costs in the 6 months following hospitalization. Transitional care intervention design should consider impacts on patient and caregiver spending. Clinicaltrials.gov # is NCT03339271.
clinical, laboratory and trichoscopic features of pediatric androgenetic alopecia: a retrospective analysis in 133 patients
Lu, Changpei, Fan, Yige, Du, Yimei , Bi, Lingbo , Wang, Chaofan , Zhao, Min , Ding, yunbu, Wei-xin, FAN, Ding, Yunbu , Wei-xin, FAN

Mayo Clinic

No container title available | May 2, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4312979/v1 Get It

Abstract This retrospective study from Jiangsu Province Hospital elucidates the prevalence and impact of pediatric androgenetic alopecia (AGA). Over a period of 14 years, 133 patients under the age of 18 were studied, with manifestations appearing as early as 8 years of age. Of note, 39.8% had an overweight/obese and 78.2% reported a family history of AGA. Comorbidities included seborrhoeic dermatitis (51.9%), acne (42.9%) and sleep disorders (28.6%). In addition, 4.5% had polycystic ovarian syndrome. Hormonal imbalances such as low sex hormone-binding globulin (47.1%) and vitamin D deficiency (61%) were common, as was low ferritin (23.6%). Male AGA patterns were characterised by crown thinning and temporal variations, whereas females showed crown thinning with frontal hair retention. Trichoscopic differences were observed between genders and age groups. This study highlights the importance of individualised, stepwise and comprehensive treatment, prioritising hormonal disorders and comorbidities when treating hair loss with topical minoxidil. Encouraging patients to adhere to regular medication and follow-up appointments can lead to favourable outcomes.
Vocal cord nodules caused by Mycobacterium avium infection
Chiu, C -Y, Yi, Eunhee S. , Chiu, C -Y, Bayan, Semirra L. , Cummins, Nathan W.

Mayo Clinic

QJM: An International Journal of Medicine | May 2, 2024 | Volume: 117 | Issue: 9 | Pages: 667-668

10.1093/qjmed/hcae091 | PMID 38696764 Get It

MOG Antibody–Associated Disease in the Setting of Metastatic Melanoma Complicated by Immune Checkpoint Inhibitor Use
Zhao-Fleming, Hannah , Guo, Yong , Tisavipat, Nanthaya , Chen, John J. , Ζεκερίδου, Αναστασία , Kournoutas, Ioannis , Orme, Jacob J. , Block, Matthew S. , Lucchinetti, Claudia F. , Syc-Mazurek, Stephanie B , Guo, Yong , Tisavipat, Nanthaya , Chen, John J , Zekeridou, Anastasia , Mustafa, Rafid , Flanagan, E P , Syc‐Mazurek, Stephanie B. , Mustafa, Rafid , Flanagan, Eoin P.

Mayo Clinic

Neurology Neuroimmunology & Neuroinflammation | May 2, 2024 | Volume: 11 | Issue: 4 | Pages: No page available

10.1212/nxi.0000000000200249 | PMID 38696737 Get It

Pragmatic strategies to address health disparities along the continuum of care in chronic liver disease
Brahmania, Mayur , Rogal, Shari S. , Serper, Marina , Goldberg, David S. , Mathur, Amit K. , Wilder, Julius , Vittorio, Jennifer , Yeoman, Andrew D. , Lazo, Mariana , Kardashian, Ani , Verma, Manisha , Verna, Elizabeth C. , Simpson, Dinee C. , Rosenblatt, Russell , McElroy, Lisa M. , Wadwhani, Sharad I., Strauss, Alexandra T. , Aiza, Ignacio , Carr, Rotonya M. , Yang, Jin Mo , Brady, Carla W. , Fortune, Brett E. , Rogal, Shari , Patel, Arpan , Goldberg, David , Mathur, Amit , Wilder, Julius , Vittorio, Jennifer M , Yeoman, Andrew , Lazo, Mariana , Kardashian, Ani , Asrani, Sumeet K , Spann, Ashley , Ufere, Nneka N , Verma, Manisha , Verna, Elizabeth C , Simpson, Dinee , Schold, Jesse D , Rosenblatt, Russell , McElroy, Lisa M , Wadhwani, Sharad I , Lee, Tzu-Hao , Strauss, Alexandra T , Aiza, Ignacio , Carr, Rotonya M , Yang, Jin Mo , Brady, Carla , Serper, Marina , Patel, Arpan , Rich, Nicole E. , Asrani, Sumeet K. , Spann, Ashley , Lee, Tzu‐Hao , Chung, Raymond T.

Mayo Clinic

Hepatology Communications | May 2, 2024 | Volume: 8 | Issue: 5 | Pages: No page available

10.1097/hc9.0000000000000413 | PMID 38696374 Get It

Racial, ethnic, and socioeconomic disparities exist in the prevalence and natural history of chronic liver disease, access to care, and clinical outcomes. Solutions to improve health equity range widely, from digital health tools to policy changes. The current review outlines the disparities along the chronic liver disease health care continuum from screening and diagnosis to the management of cirrhosis and considerations of pre-liver and post-liver transplantation. Using a health equity research and implementation science framework, we offer pragmatic strategies to address barriers to implementing high-quality equitable care for patients with chronic liver disease.
Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia
Gui, Gege , Ravindra, Niveditha , Andrew, Georgia , Mukherjee, Devdeep , Huang, Ying , Gerhold, Jason, Holman, Matt, D'Angelo, J., Miller, Jeffrey E. , Salk, Jesse J. , Jimenez-Jimenez, Antonio Martin, Lima, Marcos J.G. De, Litzow, Mark R. , Saber, Wael , Page, Kristin , Dillon, Laura Williams , Wong, Zoë C. , D’Angelo, Julian, Higgins, Jake , Auletta, Jeffery J. , Chaer, Firas El , Devine, Steven M. , Kebriaei, Partow , Spellman, Stephen R. , Zeger, Scott L. , Hourigan, Christopher S.

Mayo Clinic

JAMA Oncology | May 2, 2024 | Volume: 10 | Issue: 8 | Pages: 1104

10.1001/jamaoncol.2024.0985 | PMID 38696205 Get It

ImportancePersistence of FLT3 internal tandem duplication (ITD) in adults with acute myeloid leukemia (AML) in first complete remission (CR) prior to allogeneic hematopoietic cell transplant (HCT) is associated with increased relapse and death after transplant, but the association between the level of measurable residual disease (MRD) detected and clinical outcome is unknown.ObjectiveTo examine the association between pre–allogeneic HCT MRD level with relapse and death posttransplant in adults with AML in first CR.Design, Setting, and ParticipantsIn this cohort study, DNA sequencing was performed on first CR blood from patients with FLT3-ITD AML transplanted from March 2013 to February 2019. Clinical follow-up was through May 2022. Data were analyzed from October 2022 to December 2023.ExposureCentralized DNA sequencing for FLT3-ITD in pre–allogeneic HCT first CR blood using a commercially available kit.Main Outcomes and MeasuresThe primary outcomes were overall survival and cumulative incidence of relapse, with non–relapse-associated mortality as a competing risk post–allogeneic HCT. Kaplan-Meier estimations (log-rank tests), Cox proportional hazards models, and Fine-Gray models were used to estimate the end points.ResultsOf 537 included patients with FLT3-ITD AML from the Pre-MEASURE study, 296 (55.1%) were female, and the median (IQR) age was 55.6 (42.9-64.1) years. Using the variant allele fraction (VAF) threshold of 0.01% or greater for MRD positivity, the results closely aligned with those previously reported. With no VAF threshold applied (VAF greater than 0%), 263 FLT3-ITD variants (median [range] VAF, 0.005% [0.0002%-44%]), and 177 patients (33.0%) with positive findings were identified. Multivariable analyses showed that residual FLT3-ITD was the variable most associated with relapse and overall survival, with a dose-dependent correlation. Patients receiving reduced-intensity conditioning without melphalan or nonmyeloablative conditioning had increased risk of relapse and death at any given level of MRD compared with those receiving reduced-intensity conditioning with melphalan or myeloablative conditioning.Conclusions and RelevanceThis study provides generalizable and clinically applicable evidence that the detection of residual FLT3-ITD in the blood of adults in first CR from AML prior to allogeneic HCT is associated with an increased risk of relapse and death, particularly for those with a VAF of 0.01% or greater. While transplant conditioning intensification, an intervention not available to all, may help mitigate some of this risk, alternative approaches will be necessary for this high-risk population of patients who are underserved by the current standard of care.
Albumin Oxidation and Albumin Glycation Discordance During Type 2 Diabetes Therapy: Biological and Clinical Implications
Vaishnav, Madhumati S. , Srikanta, S. , Simha, Vinaya , Krishnaswamy, P. R., Balaram, P. , Bhat, Navakanta , Srikanta, Sathyanarayana , Kumari, Namita

Mayo Clinic

Metabolic Syndrome and Related Disorders | May 2, 2024 | Volume: 22 | Issue: 5 | Pages: 372-384

10.1089/met.2023.0275 | PMID 38696648 Get It

The Population-Level Prevalence of Exocrine Pancreas Insufficiency and the Subsequent Risk of Pancreatic Cancer
Babajide, Oyedotun , Eruchalu, Chinelo J., Sedarous, Mary , Adekunle, Ayooluwatomiwa D. , Mahmud, Muftah, Okafor, Philip N. , Desai, Aakash , Sedarous, Mary , Youssef, Michael

Mayo Clinic

Pancreas | May 2, 2024 | Volume: 53 | Issue: 9 | Pages: e723-e728

10.1097/mpa.0000000000002359 | PMID 38696443 Get It

Objectives The aim of this study was to study the prevalence of exocrine pancreas insufficiency (EPI) at a population level and the subsequent risk of pancreatic ductal adenocarcinoma (PDAC). Materials and Methods Using TriNetX (a database of over 79 million US residents), we included patients ≥18 years with EPI (identified via ICD-10 codes) and continuous follow-up from 2016–2022. Patients with prior pancreas resection and PDAC before an EPI diagnosis were excluded. The primary outcome was EPI prevalence. Secondary outcomes included imaging utilization, PDAC risk, and pancreatic enzyme replacement therapy (PERT) utilization. We performed 1:1 propensity score matching (PSM) of patients with EPI versus patients without an EPI diagnosis. Results The population prevalence of EPI was 0.8% (n = 24,080) with a mean age of 55.6 years. After PSM, PDAC risk among patients with EPI was twice as high compared with patients without EPI (aHR, 1.97; 95% CI, 1.66–2.36). This risk persisted even after excluding patients with a history of acute or chronic pancreatitis (adjusted odds ratio, 4.25; 95% CI, 2.99–6.04). Only 58% (n = 13, 390) of patients with EPI received PERT. No difference was observed in PDAC risk between patients with EPI on PERT and those not on PERT (aHR, 1.10; 95% CI, 0.95–1.26; P = 0.17). Conclusions Despite a low prevalence, patients with EPI may have a higher risk of PDAC, and majority with EPI were not on PERT. PERT did not impact incident PDAC risk after an EPI diagnosis.
Corticosteroid-induced hyperammonaemic encephalopathy in a woman with late-onset ornithine transcarbamylase deficiency
McCormick, Benjamin J. , Ritchie, Leanna V, Porter, Ivan E. , McCormick, Benjamin J , Ritchie, Leanna V.

Mayo Clinic

BMJ Case Reports | May 2, 2024 | Volume: 17 | Issue: 5 | Pages: e255793

10.1136/bcr-2023-255793 | PMID 38697679 Get It

Ornithine transcarbamylase deficiency (OTCD) is a rare, X linked disorder that can manifest in late adulthood in heterozygous females as severe hyperammonaemia following environmental stressors. We present a case of hyperammonaemic encephalopathy that was triggered by glucocorticoid administration in an adult woman with heterozygous OTCD with clinical response to haemodialysis, ammonia scavengers and a high-calorie, low-protein diet.